WEST SACRAMENTO, Calif.--(BUSINESS WIRE)--Molecular Matrix, Inc. (MMI), a leader in regenerative medicine polymer technology, is proud to announce the full launch of its Osteo-P® Synthetic Bone Graft Substitute (BGS) for use in the musculoskeletal system.
Osteo-P® BGS is made using MMI’s hyper-crosslinked carbohydrate polymer (HCCP) technology platform which has been engineered to optimize the microenvironment for bone repair and regeneration. This technology was originally developed to support the three-dimensional proliferation and differentiation of stem cells for research. Its continuous, open, interconnected matrix becomes sponge-like and flexible when hydrated with normal saline. Osteo-P® is provided in granule, cube, and strip configurations of varying sizes.
Osteo-P® BGS represents an evolution in bone grafting as a departure from the traditional calcium phosphate, bioactive glass, hydroxyapatite materials pervasive in the market today. Further, Osteo-P® BGS’s natural matrix does not require the addition of a collagen xenograft or other binder to improve handling. In addition, Osteo-P® BGS provides an opportunity for real time healing visualization, as deposition of calcium phosphate can be readily observed radiographically as remodeling takes place.
Kee Kim, MD, has this to say about Osteo-P® BGS; “I have been using Osteo-P® BGS in my surgical procedures where bone grafting is indicated and have been pleased with its ease of use and the outcome in my patients.”
Charles Lee, PhD, the CEO of MMI points out “Osteo-P® BGS is a culmination of scientific knowledge that we have learned in tissue engineering in the past few decades. Its platform technology (HCCP) is chemically versatile, which allows the incorporation of various biological signals for tissue regeneration for patients with life-threatening degenerative conditions. Through our tissue regeneration technology, MMI strives to provide humankind with one billion quality life years.”
About Molecular Matrix
Molecular Matrix is a regenerative medicine company focusing on the development of drug, gene and cell delivery vehicles based on its proprietary HCCP and Click Chemistry Technology. The company is headquartered in West Sacramento. Molecular Matrix’s first commercially available product, Osteo-P, was 510k cleared by the FDA in 2017 and has been implanted in patients since 2018 on a limited basis.